Global Information
회사소개 | 문의 | 비교리스트

세계의 전임상 이미징(In-VIVO) 시장

Preclinical Imaging (In-VIVO)

리서치사 Global Industry Analysts, Inc.
발행일 2021년 04월 상품코드 958472
페이지 정보 영문 122 Pages 배송안내 1-2일 (영업일 기준)
가격
US $ 4,950 ₩ 6,436,000 PDF (Single User License)
US $ 14,850 ₩ 19,310,000 PDF (Global License to Company and its Fully-owned Subsidiaries)


세계의 전임상 이미징(In-VIVO) 시장 Preclinical Imaging (In-VIVO)
발행일 : 2021년 04월 페이지 정보 : 영문 122 Pages

본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문목차를 참고해주시기 바랍니다.

세계 전임상 이미징(In-VIVO) 시장 규모는 분석기간(2020년-2027년)에 4.8%의 연평균 복합 성장률(CAGR)로 성장할 전망이며, 2020년 7억 8,250만 달러에서 2027년에는 11억 달러에 달할 것으로 예측됩니다. 본 보고서에서 분석한 부문 중 하나인 전임상 이미징 모달리티는 분석기간 중 5.2%의 CAGR을 나타내고, 6억 8,160만 달러에 달할 전망입니다.

세계의 전임상 이미징(In-VIVO) 시장에 대해 조사했으며, 시장 점유율, 동향 및 전망, 성장요인, 지역별 시장 분석, 경쟁 구도, 주요 기업 개요 등의 정보를 정리하여 전해드립니다.

조사 대상 기업 사례

  • Aspect Imaging
  • Bruker Corporation
  • FUJIFILM Holdings Corporation
  • LI-COR, Inc. (LI-COR Biosciences)
  • Mediso Ltd.
  • MILabs BV
  • Miltenyi Biotec GmbH
  • MR Solutions Ltd.
  • PerkinElmer, Inc.
  • Trifoil Imaging, Inc.

목차

I. 서론, 조사 방법, 조사 범위

II. 주요 요약

  • 시장 개요
    • Covid-19의 영향과 다가오는 세계의 경기후퇴
    • 경쟁사의 시장 점유율
    • 경쟁사의 시장 점유율 시나리오
  • 주요 기업
  • 동향과 성장 촉진요인
  • 세계 시장 전망

III. 시장 분석

  • 지역별 시장 분석
  • 미국
  • 캐나다
  • 일본
  • 중국
  • 유럽
  • 프랑스
  • 독일
  • 이탈리아
  • 영국
  • 기타 유럽
  • 아시아태평양
  • 기타 지역

IV. 경쟁

  • 기업 개요 : 65사
KSM 20.09.29

Abstract:

Global Preclinical Imaging (In-VIVO) Market to Reach $1.1 Billion by 2027

Amid the COVID-19 crisis, the global market for Preclinical Imaging (In-VIVO) estimated at US$782.5 Million in the year 2020, is projected to reach a revised size of US$1.1 Billion by 2027, growing at aCAGR of 4.8% over the period 2020-2027. Preclinical imaging modalities, one of the segments analyzed in the report, is projected to record 5.2% CAGR and reach US$681.6 Million by the end of the analysis period. After an early analysis of the business implications of the pandemic and its induced economic crisis, growth in the Preclinical imaging reagents segment is readjusted to a revised 4.2% CAGR for the next 7-year period.

The U.S. Market is Estimated at $230.5 Million, While China is Forecast to Grow at 4.5% CAGR

The Preclinical Imaging (In-VIVO) market in the U.S. is estimated at US$230.5 Million in the year 2020. China, the world`s second largest economy, is forecast to reach a projected market size of US$191.7 Million by the year 2027 trailing a CAGR of 4.5% over the analysis period 2020 to 2027. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 4.6% and 3.7% respectively over the 2020-2027 period. Within Europe, Germany is forecast to grow at approximately 3.9% CAGR.

Select Competitors (Total 38 Featured) -

  • Aspect Imaging Ltd.
  • Bruker Corp.
  • Idex Health & Science LLC
  • Mauna Kea Technologies
  • Mediso Ltd.
  • Milabs B.V.
  • Miltenyi Biotech GmbH
  • MR Solutions
  • New England Biolabs
  • PerkinElmer, Inc.
  • Siemens A.G.
  • Trifoil Imaging, Inc.
  • FujiFilm VisualSonics, Inc.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • World Market Trajectories
    • Impact of Covid-19 and a Looming Global Recession
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Current & Future Analysis for Preclinical Imaging (In-VIVO) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2018 through 2027 and % CAGR
    • TABLE 2: World Historic Review for Preclinical Imaging (In-VIVO) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2017 and % CAGR
    • TABLE 3: World 15-Year Perspective for Preclinical Imaging (In-VIVO) by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2012, 2018 & 2027
    • TABLE 4: World Current & Future Analysis for Preclinical imaging modalities by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2018 through 2027 and % CAGR
    • TABLE 5: World Historic Review for Preclinical imaging modalities by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2017 and % CAGR
    • TABLE 6: World 15-Year Perspective for Preclinical imaging modalities by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2018 & 2027
    • TABLE 7: World Current & Future Analysis for Preclinical imaging reagents by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2018 through 2027 and % CAGR
    • TABLE 8: World Historic Review for Preclinical imaging reagents by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2017 and % CAGR
    • TABLE 9: World 15-Year Perspective for Preclinical imaging reagents by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2018 & 2027

III. MARKET ANALYSIS

  • UNITED STATES
    • TABLE 10: USA Current & Future Analysis for Preclinical Imaging (In-VIVO) by Segment - Preclinical imaging modalities and Preclinical imaging reagents - Independent Analysis of Annual Sales in US$ Thousand for the Years 2018 through 2027 and % CAGR
    • TABLE 11: USA Historic Review for Preclinical Imaging (In-VIVO) by Segment - Preclinical imaging modalities and Preclinical imaging reagents Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2017 and % CAGR
    • TABLE 12: USA 15-Year Perspective for Preclinical Imaging (In-VIVO) by Segment - Percentage Breakdown of Value Sales for Preclinical imaging modalities and Preclinical imaging reagents for the Years 2012, 2018 & 2027
  • CANADA
    • TABLE 13: Canada Current & Future Analysis for Preclinical Imaging (In-VIVO) by Segment - Preclinical imaging modalities and Preclinical imaging reagents - Independent Analysis of Annual Sales in US$ Thousand for the Years 2018 through 2027 and % CAGR
    • TABLE 14: Canada Historic Review for Preclinical Imaging (In-VIVO) by Segment - Preclinical imaging modalities and Preclinical imaging reagents Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2017 and % CAGR
    • TABLE 15: Canada 15-Year Perspective for Preclinical Imaging (In-VIVO) by Segment - Percentage Breakdown of Value Sales for Preclinical imaging modalities and Preclinical imaging reagents for the Years 2012, 2018 & 2027
  • JAPAN
    • TABLE 16: Japan Current & Future Analysis for Preclinical Imaging (In-VIVO) by Segment - Preclinical imaging modalities and Preclinical imaging reagents - Independent Analysis of Annual Sales in US$ Thousand for the Years 2018 through 2027 and % CAGR
    • TABLE 17: Japan Historic Review for Preclinical Imaging (In-VIVO) by Segment - Preclinical imaging modalities and Preclinical imaging reagents Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2017 and % CAGR
    • TABLE 18: Japan 15-Year Perspective for Preclinical Imaging (In-VIVO) by Segment - Percentage Breakdown of Value Sales for Preclinical imaging modalities and Preclinical imaging reagents for the Years 2012, 2018 & 2027
  • CHINA
    • TABLE 19: China Current & Future Analysis for Preclinical Imaging (In-VIVO) by Segment - Preclinical imaging modalities and Preclinical imaging reagents - Independent Analysis of Annual Sales in US$ Thousand for the Years 2018 through 2027 and % CAGR
    • TABLE 20: China Historic Review for Preclinical Imaging (In-VIVO) by Segment - Preclinical imaging modalities and Preclinical imaging reagents Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2017 and % CAGR
    • TABLE 21: China 15-Year Perspective for Preclinical Imaging (In-VIVO) by Segment - Percentage Breakdown of Value Sales for Preclinical imaging modalities and Preclinical imaging reagents for the Years 2012, 2018 & 2027
  • EUROPE
    • TABLE 22: Europe Current & Future Analysis for Preclinical Imaging (In-VIVO) by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2018 through 2027 and % CAGR
    • TABLE 23: Europe Historic Review for Preclinical Imaging (In-VIVO) by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2017 and % CAGR
    • TABLE 24: Europe 15-Year Perspective for Preclinical Imaging (In-VIVO) by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2012, 2018 & 2027
    • TABLE 25: Europe Current & Future Analysis for Preclinical Imaging (In-VIVO) by Segment - Preclinical imaging modalities and Preclinical imaging reagents - Independent Analysis of Annual Sales in US$ Thousand for the Years 2018 through 2027 and % CAGR
    • TABLE 26: Europe Historic Review for Preclinical Imaging (In-VIVO) by Segment - Preclinical imaging modalities and Preclinical imaging reagents Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2017 and % CAGR
    • TABLE 27: Europe 15-Year Perspective for Preclinical Imaging (In-VIVO) by Segment - Percentage Breakdown of Value Sales for Preclinical imaging modalities and Preclinical imaging reagents for the Years 2012, 2018 & 2027
  • FRANCE
    • TABLE 28: France Current & Future Analysis for Preclinical Imaging (In-VIVO) by Segment - Preclinical imaging modalities and Preclinical imaging reagents - Independent Analysis of Annual Sales in US$ Thousand for the Years 2018 through 2027 and % CAGR
    • TABLE 29: France Historic Review for Preclinical Imaging (In-VIVO) by Segment - Preclinical imaging modalities and Preclinical imaging reagents Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2017 and % CAGR
    • TABLE 30: France 15-Year Perspective for Preclinical Imaging (In-VIVO) by Segment - Percentage Breakdown of Value Sales for Preclinical imaging modalities and Preclinical imaging reagents for the Years 2012, 2018 & 2027
  • GERMANY
    • TABLE 31: Germany Current & Future Analysis for Preclinical Imaging (In-VIVO) by Segment - Preclinical imaging modalities and Preclinical imaging reagents - Independent Analysis of Annual Sales in US$ Thousand for the Years 2018 through 2027 and % CAGR
    • TABLE 32: Germany Historic Review for Preclinical Imaging (In-VIVO) by Segment - Preclinical imaging modalities and Preclinical imaging reagents Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2017 and % CAGR
    • TABLE 33: Germany 15-Year Perspective for Preclinical Imaging (In-VIVO) by Segment - Percentage Breakdown of Value Sales for Preclinical imaging modalities and Preclinical imaging reagents for the Years 2012, 2018 & 2027
  • ITALY
    • TABLE 34: Italy Current & Future Analysis for Preclinical Imaging (In-VIVO) by Segment - Preclinical imaging modalities and Preclinical imaging reagents - Independent Analysis of Annual Sales in US$ Thousand for the Years 2018 through 2027 and % CAGR
    • TABLE 35: Italy Historic Review for Preclinical Imaging (In-VIVO) by Segment - Preclinical imaging modalities and Preclinical imaging reagents Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2017 and % CAGR
    • TABLE 36: Italy 15-Year Perspective for Preclinical Imaging (In-VIVO) by Segment - Percentage Breakdown of Value Sales for Preclinical imaging modalities and Preclinical imaging reagents for the Years 2012, 2018 & 2027
  • UNITED KINGDOM
    • TABLE 37: UK Current & Future Analysis for Preclinical Imaging (In-VIVO) by Segment - Preclinical imaging modalities and Preclinical imaging reagents - Independent Analysis of Annual Sales in US$ Thousand for the Years 2018 through 2027 and % CAGR
    • TABLE 38: UK Historic Review for Preclinical Imaging (In-VIVO) by Segment - Preclinical imaging modalities and Preclinical imaging reagents Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2017 and % CAGR
    • TABLE 39: UK 15-Year Perspective for Preclinical Imaging (In-VIVO) by Segment - Percentage Breakdown of Value Sales for Preclinical imaging modalities and Preclinical imaging reagents for the Years 2012, 2018 & 2027
  • REST OF EUROPE
    • TABLE 40: Rest of Europe Current & Future Analysis for Preclinical Imaging (In-VIVO) by Segment - Preclinical imaging modalities and Preclinical imaging reagents - Independent Analysis of Annual Sales in US$ Thousand for the Years 2018 through 2027 and % CAGR
    • TABLE 41: Rest of Europe Historic Review for Preclinical Imaging (In-VIVO) by Segment - Preclinical imaging modalities and Preclinical imaging reagents Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2017 and % CAGR
    • TABLE 42: Rest of Europe 15-Year Perspective for Preclinical Imaging (In-VIVO) by Segment - Percentage Breakdown of Value Sales for Preclinical imaging modalities and Preclinical imaging reagents for the Years 2012, 2018 & 2027
  • ASIA-PACIFIC
    • TABLE 43: Asia-Pacific Current & Future Analysis for Preclinical Imaging (In-VIVO) by Segment - Preclinical imaging modalities and Preclinical imaging reagents - Independent Analysis of Annual Sales in US$ Thousand for the Years 2018 through 2027 and % CAGR
    • TABLE 44: Asia-Pacific Historic Review for Preclinical Imaging (In-VIVO) by Segment - Preclinical imaging modalities and Preclinical imaging reagents Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2017 and % CAGR
    • TABLE 45: Asia-Pacific 15-Year Perspective for Preclinical Imaging (In-VIVO) by Segment - Percentage Breakdown of Value Sales for Preclinical imaging modalities and Preclinical imaging reagents for the Years 2012, 2018 & 2027
  • REST OF WORLD
    • TABLE 46: Rest of World Current & Future Analysis for Preclinical Imaging (In-VIVO) by Segment - Preclinical imaging modalities and Preclinical imaging reagents - Independent Analysis of Annual Sales in US$ Thousand for the Years 2018 through 2027 and % CAGR
    • TABLE 47: Rest of World Historic Review for Preclinical Imaging (In-VIVO) by Segment - Preclinical imaging modalities and Preclinical imaging reagents Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2017 and % CAGR
    • TABLE 48: Rest of World 15-Year Perspective for Preclinical Imaging (In-VIVO) by Segment - Percentage Breakdown of Value Sales for Preclinical imaging modalities and Preclinical imaging reagents for the Years 2012, 2018 & 2027

IV. COMPETITION

  • Total Companies Profiled: 38
Back to Top
전화 문의
F A Q